10-K/A: Bionexus Gene Lab Corp. Amends 2022 Annual Report Following SEC Comment

Bionexus Gene Lab Corp. has filed an amendment to its 2022 annual report to correct inaccuracies regarding its internal controls and procedures, following a comment letter from the SEC.

Summary

• Bionexus Gene Lab Corp. filed an amendment to its original 2022 annual report on Form 10-K/A.
• The amendment specifically addresses and corrects inaccuracies in Part II, Item 9A, concerning Controls and Procedures.
• The original filing incorrectly stated that the company had a material weakness in internal control over financial reporting due to a single officer and director and a lack of a functioning audit committee.
• The company clarifies that at the time of the original filing, it had five officers, four directors, and an audit committee comprised of three independent directors.
• The amendment does not change any of the financial statements from the original filing.
• The company's management concluded that its disclosure controls and procedures were not effective as of December 31, 2022, due to the inaccuracies in the original filing.
• Management also concluded that the internal control over financial reporting was effective, correcting the previous statement of a material weakness.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the need for an amendment to correct significant errors in the original filing, particularly regarding internal controls. While the company has addressed the issues, the initial missteps raise concerns.

Positives

• The company has corrected inaccuracies in its original filing regarding internal controls and procedures.
• The company clarified that it had a functioning audit committee with independent directors, contrary to the original report.
• Management has corrected the statement of a material weakness in internal control over financial reporting, now stating that it was effective as of December 31, 2022.

Negatives

• The company's disclosure controls and procedures were deemed ineffective as of December 31, 2022, due to the inaccuracies in the original filing.
• The original filing contained inaccurate information regarding the company's management structure and audit committee.

Risks

• The initial misstatement of internal controls and procedures could raise concerns about the reliability of the company's reporting processes.
• The need for an amendment indicates potential weaknesses in the company's initial reporting and review processes.
• The company's disclosure controls and procedures were deemed ineffective as of December 31, 2022, which could lead to future reporting issues.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Management Comments

• Management concluded that the company's disclosure controls and procedures were not effective as of December 31, 2022, due to inaccuracies in the original filing.
• Management concluded that the internal control over financial reporting was effective as of December 31, 2022, correcting the previous statement of a material weakness.
• The CEO and Acting CFO, Su-Leng Tan Lee, certified that the report does not contain any untrue statement of a material fact.

Industry Context

This amendment highlights the importance of accurate financial reporting and internal controls, which are critical for maintaining investor confidence and regulatory compliance in the biotechnology industry. It also underscores the SEC's scrutiny of these areas.

Comparison to Industry Standards

• The need for an amendment to correct errors in internal control reporting is not uncommon, but it does raise concerns about the robustness of Bionexus Gene Lab Corp.'s initial reporting processes.
• Companies like Myriad Genetics and Exact Sciences, which are also in the genetic testing space, are expected to maintain high standards of internal control and financial reporting.
• The fact that Bionexus Gene Lab Corp. had to amend its report to correct errors in its internal control assessment is a deviation from the best practices of larger, more established companies in the sector.

Stakeholder Impact

• Shareholders may be concerned about the initial inaccuracies in the company's reporting.
• The amendment could impact investor confidence in the company's financial reporting processes.
• The company's management is under scrutiny to ensure accurate and reliable reporting in the future.

Key Dates

Keywords

internal controls, financial reporting, disclosure controls, SEC, amendment, audit committee, material weakness, Form 10-K/A